In this cohort study of older Medicare beneficiaries with ERBB2-positive breast cancer, we observed a narrowing of racial and ethnic disparities in ERBB2-targeted therapy from 2010-2011 to 2018-2019. The gene discussed is ERBB2; the disease is breast carcinoma.